Hemophilia B Clinical Trials

22 recruiting

Hemophilia B Trials at a Glance

24 actively recruiting trials for hemophilia b are listed on ClinicalTrialsFinder across 6 cities in 34 countries. The largest study group is Phase 1 with 7 trials, with the heaviest enrollment activity in Tianjin, London, and Ann Arbor. Lead sponsors running hemophilia b studies include Institute of Hematology & Blood Diseases Hospital, China, CSL Behring, and Pfizer.

Browse hemophilia b trials by phase

Treatments under study

About Hemophilia B Clinical Trials

Looking for clinical trials for Hemophilia B? There are currently 22 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hemophilia B trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hemophilia B clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 24 trials

Recruiting
Phase 3

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

Hemophilia AHemophilia B
Pfizer173 enrolled17 locationsNCT05568719
Recruiting
Phase 1

Lentiviral FIX Gene Therapy

Hemophilia B
Shenzhen Geno-Immune Medical Institute10 enrolled1 locationNCT03961243
Recruiting

Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders

Cystic FibrosisHuntington DiseaseSickle Cell Disease+12 more
Assistance Publique - Hôpitaux de Paris550 enrolled1 locationNCT06147414
Recruiting

ATHNdataset Registry

ThrombosisSickle Cell DiseaseHemophilia A+6 more
American Thrombosis and Hemostasis Network200,000 enrolled1 locationNCT06820515
Recruiting
Phase 3

Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

Hemophilia B
CSL Behring20 enrolled10 locationsNCT07080905
Recruiting
Phase 1Phase 2

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

Hemophilia B
Regeneron Pharmaceuticals130 enrolled41 locationsNCT06379789
Recruiting
Phase 3

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

Hemophilia AHemophilia B
Pfizer245 enrolled75 locationsNCT05145127
Recruiting
Phase 3

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

Hemophilia AHemophilia B
Pfizer100 enrolled66 locationsNCT05611801
Recruiting
Phase 3

Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

Hemophilia B
CSL Behring35 enrolled26 locationsNCT06003387
Recruiting
Phase 1

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)

Healthy ParticipantsHemophilia AHemophilia B+1 more
Equilibra Bioscience LLC31 enrolled10 locationsNCT06349473
Recruiting

An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B

Hemophilia B
CSL Behring500 enrolled12 locationsNCT06008938
Recruiting

National Longitudinal Cohort of Hematological Diseases

Acute Myeloid LeukemiaMultiple MyelomaMyelodysplastic Syndrome+14 more
Institute of Hematology & Blood Diseases Hospital, China2,300 enrolled1 locationNCT04645199
Recruiting
Phase 4

SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

Hemophilia A With InhibitorHemophilia B With Inhibitor
American Thrombosis and Hemostasis Network55 enrolled21 locationsNCT04647227
Recruiting
Phase 3

An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B

Hemophilia B
Biocad24 enrolled14 locationsNCT06700096
Recruiting
Phase 1Phase 2

BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B

Hemophilia BHemophilia B, Moderately Severe or Severe
Be Biopharma24 enrolled4 locationsNCT06611436
Recruiting
Phase 1Phase 2

Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)

Hemophilia B
Biocad28 enrolled17 locationsNCT06120582
Recruiting
Phase 1

Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old

Hemophilia B
Institute of Hematology & Blood Diseases Hospital, China9 enrolled1 locationNCT05709288
Recruiting
Early Phase 1

Safety and Tolerability of VGB-R04 in Patients With Haemophilia B

Hemophilia B
Institute of Hematology & Blood Diseases Hospital, China3 enrolled1 locationNCT05152732
Recruiting
Not Applicable

The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.

Hemophilia B
Institute of Hematology & Blood Diseases Hospital, China6 enrolled1 locationNCT05630651
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients

Hemophilia B
Institute of Hematology & Blood Diseases Hospital, China21 enrolled1 locationNCT05641610